NCT04691817View on ClinicalTrials.gov

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 25, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

September 30, 2026

Conditions
Lung Cancer, Nonsmall Cell
Interventions
DRUG

Atezolizumab

1200mg infusion

DRUG

Tocilizumab

Tocilizumab 6mg/kg or 4mg/kg infusion

Trial Locations (1)

19104

RECRUITING

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Abramson Cancer Center at Penn Medicine

OTHER